Patient Capital And Regulatory Resolve: Dr Reddy’s Chief On Building India's Innovation Backbone

In this podcast, Satish Reddy, chairman of Dr. Reddy's Laboratories, talks about deploying generic Revlimid gains strategically, building a diversified growth engine, what India must fix — regulatory science, risk capital and more — to become a serious innovation force, and learnings from China. A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. #pharma #biotech #India #China #funding #Supply chain #business strategy #regulation